CD19 and diffuse large B-cell lymphoma: Most importantly, patients with R/R DLBCL or MCL can be offered adoptive immunotherapy based on ex vivo expanded autologous T-cells with genetically engineered chimeric antigen receptors (CARs) targeted against CD19 antigens (CAR19 T-cells) [15,16,17,18].